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Existing devices for early infant male circumcision (EIMC) have inherent limitations. We
evaluated the newly developed AccuCirc device by circumcising 151 clinically well, full-term
male infants with birth-weight ≥ 2.5 kg within the first 10 days of life from a convenience sample
in two hospitals in Botswana. No major adverse events were observed. There was one local
infection, five cases of minor bleeding and one case of moderate bleeding. In three cases the
device made only partial incisions that were completed immediately by the provider without
complications. Parental satisfaction was high: > 96% of mothers stated they would circumcise a
future son. The pre-assembled, sterile AccuCirc kit has the potential to overcome obstacles related
to supply chain management and on-site instrument disinfection that can pose challenges in
resource-limited settings. In our study the AccuCirc was safe and it should be considered for
programmatic EIMC in resource-limited settings.
BACKGROUND
Randomized trials have provided compelling evidence that male circumcision (MC) reduces
men’s risk of heterosexually-acquired HIV-1 infection by about 60% [1–3] and it has been
shown to be a cost-saving intervention in sub-Saharan Africa [4, 5]. Although there have
been no prospective randomized trials specifically demonstrating a protective effect of MC
against HIV when done before adulthood, observational studies and models suggest that the
cost-benefit and safety appear to be greatest when the procedure is done in early infancy [6–
9]. The World Health Organization (WHO) recommends MC as a component of
comprehensive HIV prevention programming and identifies neonatal circumcision as a
lower-risk procedure with fewer complications than circumcision performed at older ages.
WHO recommends that “countries should consider how to promote neonatal circumcision in
a safe, culturally acceptable and sustainable manner” [8].
Specialized devices are required for safe early infant male circumcision (EIMC, performed ≤
60 days of life [10]), and it is important to provide programs with options for devices that
suit local needs so that this evidence-based HIV prevention strategy can be optimized and
successfully implemented in routine public health settings. In 2010, WHO published the
Manual for Early Infant Male Circumcision under Local Anaesthesia [10], which included
the Mogen, Gomco and Plastibell devices. At the time of publication, the AccuCirc was a
new EIMC device (approved by the United States Food and Drug Administration in 2007)
and it had not yet undergone field evaluation to assess its performance in resource-limited
settings.
Although published reports and our own studies have shown a very low rate of serious
adverse events associated with EIMC [11–15], we believe the adverse event rate could be
decreased. There are rare but serious potential complications associated with all three
devices currently on the WHO prequalified list of EIMC devices: 1) use of the Mogen clamp
can result in partial or total amputation of the glans penis or removal of too little foreskin
[10, 13, 16–18]; 2) migration of the Plastibell can result in necrosis of the glans and other
injuries, and risk is increased if the incorrect size “bell” is utilized [10, 14, 19, 20], and 3)
mismatching the sizes of the separate pieces of the Gomco clamp can result in laceration of
the glans penis [10, 16]. Sequelae of these rare adverse outcomes may be worse in settings
with limited resources for treating such complications.
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The potential complications of these three devices are inherent in their design. Although
training and increased experience of the providers can reduce the risk of complications, the
design of the devices themselves will always present the potential for adverse events. The
AccuCirc has several safety features that make an adverse event resulting from the device
itself extremely unlikely. It is a onetime use device that has a built-in shield to protect the
glans from laceration and it incorporates a retractable blade that cannot be reused. We
therefore conducted a single-arm field-evaluation of the AccuCirc device in Botswana to
assess safety and parental satisfaction.
METHODS
Informed Consent, Safety Monitoring, and Role of the Funding Source
Written informed consent was obtained from the mothers or legal guardians (if mothers were
age <21 years, the age of majority in Botswana) before neonates were enrolled. The single-
arm study was approved by the Botswana Ministry of Health’s Health Research and
Development Committee (HRDC) and by Brigham and Women’s Hospital Institutional
Review Board (IRB). An independent Data Safety Monitoring Committee was responsible
for safety monitoring. This trial is registered with ClinicalTrials.gov with the number
NCT00971958. The sponsors of the study had no role in study design, data collection, data
analysis, data interpretation, or writing of the report. The corresponding author had full
access to all the data in the study and had final responsibility for the decision to submit for
publication. The AccuCirc devices used in this evaluation were donated by Clinical
Innovations, Murray, UT, USA.
Subjects
Mothers and infants were enrolled between February and September 2011 at two hospitals in
southeastern Botswana: one in the capital city, Gaborone, and one in the village of
Molepolole. A convenience sample of eligible mothers and infants were identified and
recruited by study staff in maternity wards in the respective hospitals. Maternal eligibility
criteria were Botswana citizenship, non-incarceration, and ability to follow-up at seven days
and six weeks after the procedure. Infant eligibility criteria were male gender, gestational
age ≥37 weeks, age ≤10 days of life, birth-weight ≥2,500 grams, no evidence of neonatal
sepsis or other illness requiring hospitalization, no family history of bleeding disorder, and
no genital or other abnormality that is a contraindication to EIMC. The maternal HIV status
was not one of the inclusion/exclusion criteria and thus was not recorded for the purposes of
this study.
AccuCirc Device, Kit and Procedure
The AccuCirc comes in a sterile pack that contains the device itself, a surgical pen, drape,
two hemostats, three betadine swabs, xeroform dressing, gauze and cleansing wipe and all
items are disposable. The device itself consists of 1) a flexible foreskin probe and shielding
ring and 2) a single-action clamp that contains a circular blade. It is available in two sizes:
1.1 cm and 1.3 cm (penile diameter). Complete manufacturer instructions are available on
line [21]. A surgical pen-mark is made on the foreskin at the level of the corona. The
physiologic adhesions between the foreskin and the glans are removed using the flexible
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foreskin probe. With the use of hemostats, the shielding ring is then inserted into the
preputial space, between the foreskin and the glans. The adjustable foreskin holder is
deployed, and using a hemostat, the tissue is aligned according to the pen-mark within the
inner and outer rings. The clamp is applied and activated to deliver a circumferential,
hemostatic crush while simultaneously incising the foreskin. After 5 minutes of hemostatic
pressure, the clamp is released and the wound is dressed (Figure 1).
Study Intervention
All circumcisions were performed by a study physician (NN, RA or RP) using clean
techniques (sterile kit and new, non-sterile gloves, in a clean clinical setting but not a
surgical theater) [12, 22]. The study physicians, who had no significant prior experience in
performing EIMC with the AccuCirc device, were trained by an AccuCirc-experienced
physician prior to study initiation and only performed procedures independently after
competency was demonstrated.
Study staff performed a physical examination to exclude infants with abnormalities
precluding circumcision. Infants had approximately one gram of eutectic mixture of local
anesthetic (EMLA) applied to the outer foreskin and shaft of the penis and covered with an
occlusive dressing (the pros and cons of various local anesthetics approved for use for EIMC
have been previously described [23] (it should be noted EMLA should not be used on the
mucosal/inner surface of the foreskin because of higher absorption possibly leading to
systemic toxicity); EMLA was wiped off prior to the procedure. During the procedure,
infants were given concentrated sucrose solution either by gloved finger or by syringe to
augment the anesthetic effect of EMLA, as has been previously described [24–26]. Infants’
upper bodies and arms were swaddled, and legs restrained by an assistant. Infants had the
genital area, lower abdomen and upper legs cleansed with betadine immediately prior to
EIMC.
After circumcision, infants were checked for post-procedure bleeding or other immediate
complications. Mothers were asked to wait with the infant for two hours following the
procedure prior to leaving the facility to ensure there was no excessive bleeding and to
ensure that the infant had urinated. Mothers were given Vaseline for wound care and written
post-procedure care instructions that included a phone number to reach a study physician 24
hours a day, seven days a week, in case of any questions or concerns.
Follow-up and Evaluation
Post-procedure follow-up visits were scheduled at seven days and six weeks. At these visits,
parents were asked about complications and child outpatient medical cards were also
reviewed for evidence of visits to non-study clinics or providers for adverse events
potentially related to the procedure. The infants also had a physical exam, including
inspection of the circumcision site, by one of the three study physicians.
Outcomes
The primary study outcomes were adverse events and parental satisfaction. We also
measured the time taken to perform the procedure from the infant’s diaper being removed
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until the time it was replaced, and recorded the number of AccuCirc devices opened so that
correct sizing was achieved.
Adverse events that were potentially related to EIMC were defined prior to study initiation
and categorized as bleeding, infection, structural and other. Minor adverse events included
bleeding requiring only the application of pressure beyond the immediate post-procedure
period, or infection limited to the circumcision site. Moderate adverse events included
intervention for bleeding other than pressure (e.g. suturing), or soft-tissue infection
spreading beyond the penis (lower abdominal wall, upper legs). Major adverse events
included the need for a separate clinic visit or hospitalization for bleeding from the
circumcision site; need for IV fluids or blood products; systemic infection/sepsis; removal of
too much or incorrect tissue; removal of too little tissue requiring repeat procedure;
structural injury to the glans, urethra or shaft; or subsequent problems with urination.
To assess parental satisfaction we used a structured questionnaire that was administered at
the six-week follow-up visit. “Highly or completely” was defined as a score of 90% or
greater on a visual analogue scale from 0 – 100%. Parents were also asked if they would be
likely to choose EIMC for a future son.
Sample Size
This was a pilot study aiming to explore the performance of the AccuCirc in resource-
limited settings. This study was not powered to detect a statistically significant difference in
major adverse events when comparing the AccuCirc with other devices (previously reported
rates of major complications following EIMC are as low as 0.2% in well-resourced settings)
[11, 12, 15].
Statistical Analysis
Frequency tables for each of the primary outcomes present proportions, means, medians,
standard deviations, and interquartile ranges as appropriate. All statistical analyses were
performed with SAS software version 9.3 (SAS Institute, Cary, NC).
RESULTS
Study Participants
We circumcised 151 infants at a median age of 2 days (IQR: 2–4 days) and a median birth
weight of 3.13 kg (IQR: 2.95–3.42 kg). On average, study participants were born at an
estimated gestational age of 39.4 weeks. Three additional infants were enrolled, but did not
undergo circumcision: two experienced a local reaction to the topical anesthesia we
previously described [23] which precluded continuing with the procedure, and one was
found, after the foreskin was retracted but prior to circumcision, to have glandular
hypospadias, which made him ineligible for the procedure. We opened 155 kits and four
infants required a different size: ultimately we used 117 size 1.1 cm and 34 size 1.3 cm
clamps. The average time required to complete a single procedure was 16.5 minutes (SD:
6.7 minutes).
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Of the 151 infants circumcised, 150 completed the 7-day follow-up visit; one child did not
return in person for any follow-up, but his parents were contacted by telephone and reported
no adverse events or complications from the procedure. One hundred and thirty seven
infants returned for the 6-week follow-up visit.
Adverse Events
We observed ten adverse events (6.6%), all of which were classified as either minor (n=9) or
moderate (n=1) (Table 1). Five cases of minor bleeding occurred (all resolved with brief,
local pressure). One case of local infection was diagnosed by a non-study physician and not
confirmed by the study team; the infant was prescribed oral amoxicillin and had no further
sequelae. In three cases the AccuCirc device made only a partial incision (cut approximately
70% of circumference) requiring manual completion by the study physician. In these three
instances, the EIMC was completed as a single procedure: immediately upon realizing that
the cut was incomplete, the provider used sterile surgical scissors to incise along the
hemostatic crush-line made by the AccuCirc device without further complications. The only
moderate adverse event involved prolonged bleeding (90 minutes) immediately following
the procedure in an infant who had inadvertently not received Botswana standard of care,
prophylactic vitamin K at birth. Bleeding resolved approximately 30 minutes after
administration of 2 mg phytomenadione (vitamin K1) intramuscularly. A complete case
report describing the event has been previously published [27].
Parental Satisfaction
Of 137 infants who returned for the 6-week follow-up visit, 91% of mothers reported being
highly or completely satisfied with the procedure; 97% stated they would highly or
completely recommend the procedure to a friend or relative. More than 96% stated that they
would circumcise another son should they have one in the future (Table 1).
DISCUSSION
In this single-arm field evaluation of the AccuCirc device for EIMC in Botswana, we
observed no major complications. Minor bleeding (3.3%), which is expected in any surgical
procedure, was similar to our previous study of EIMC using the Mogen clamp (3.2%)[14].
Although 13 children were not seen for their second scheduled follow-up visit, they were
seen by study staff for their first visit. Although complications from EIMC are rare, many
will occur immediately following (bleeding, soft-tissue injury) or within a few days of the
procedure (infection), and in evaluating the safety of the AccuCirc, these complications
were our main focus. Longer-term follow-up of issues such as unsatisfactory cosmetic result
or meatal stenosis (that may be independent of which device is used for EIMC) are beyond
the scope of this pilot study but do deserve systematic investigation. Because serious
adverse events are very rare after the immediate post-EIMC period, parental education as to
what should prompt need for follow-up (further bleeding, any fever, abnormal discoloration
or malodor of wound) should ensure optimal care. In our study design, mothers were asked
to wait with the infant for two hours following the procedure to ensure there was no
excessive bleeding and to ensure that the infant had urinated. Mothers were provided with
written instructions along with a phone number, operational 24 hours per day and seven days
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per week, for the staff physicians in case of participant questions or concerns. This may be a
model that could be replicated for scale up of EIMC programs. Parental satisfaction with the
procedure was high and > 96% of parents reported being very likely or likely to circumcise
another son in the future.
Although the device failed to completely incise the circumference of the foreskin in three
instances, no harm resulted to the infants. As the applied pressure is determined by the
device mechanics and not by the clinician deploying it, the device may need revision if this
is found to occur in larger studies. Alternatively, it could be that the clinician must make
sure that the foreskin is evenly distributed along the foreskin holder prior to deploying the
blade so as to ensure an even incision.
The potential for incomplete incisions would limit the use of the device to facilities where
standard surgical instruments, such as scissors, would be readily available until the issue has
been fully resolved.
Ideal device characteristics for scale-up of EIMC programs differ from those needed in adult
MC programs. The 60-day age limit for EIMC is based on safety data [10]. Furthermore, as
babies get older and heavier, they are more likely to bleed following the procedure and this
could negate the sutureless nature of the procedure. Because of the limited window in which
the procedure can be performed, the procedure needs to be offered in a sustained fashion
(rather than as a mass campaign) and near to where infants are born or receive health care
(rather than recruiting men from a large catchment area to come to a central location where
dozens of procedures can be done per day). EIMC programs therefore require device
characteristics suited to rural maternity clinics or home-based service provision, where
procedures will likely be performed by non-physicians and where moderate or major
complications must be minimized. Our findings suggest the safety characteristics of the
AccuCirc device may be well-suited for EIMC.
The AccuCirc device could also simplify supply chain management and eliminate the need
for reusable instrument inventory and sterilization at remote sites because it comes in a
sterile pack containing necessary supplies together with the device [28]. In contrast, use of
the Plastibell places an additional burden on supply chain management because all six sizes
must be continually stocked, and use of the Mogen and Gomco clamps require reliable and
timely instrument disinfection processes.
We would like to emphasize that the most important criteria as EIMC is operationalized is
that the infant must be clinically well before undergoing the procedure. Unfortunately
neonatal mortality continues to be unacceptably high in many parts of the world and
although the EIMC procedure itself is not likely to result in major morbidity or mortality, it
is important that such events not be erroneously ascribed to EIMC as the procedure is
scaled-up. We believe that each program will have to contextually customize inclusion
criteria, although being clinically well should always be a criterion. Context-specific
programmatic determinations will have to be made regarding timing of EIMC for those
infants who fail to meet programmatic inclusion criteria at birth (e.g. ill infants, low birth
weight, prematurity).
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In summary, we safely and acceptably circumcised 151 infants in Botswana with the
AccuCirc device. If additional field studies confirm our findings [29], the AccuCirc should
be considered for WHO pre-qualification to increase options for safe and sustainable scale-
up of EIMC in resource-limited settings.
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A) a surgical pen-mark (indicated by ---) is made on the foreskin at the level of the corona.
Adhesions are removed using the flexible foreskin probe. B) with the use of hemostats, the
shielding ring is then inserted into the preputial space, between the foreskin and the glans.
C) the adjustable foreskin holder is deployed, and D) using a hemostat, the tissue is aligned
according to the pen-mark within the inner and outer rings. E) the clamp is applied and F)
activated to deliver a circumferential, hemostatic crush while simultaneously incising the
foreskin. G) after 5 minutes of pressure, the clamp is released and the wound is dressed.
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Table 1
Adverse events and parentala satisfaction following NMC among N=150 infants circumcised with the
AccuCirc device from February to September 2011 in southeastern Botswana.
Outcome (total n with data) N (%)
Adverse Events (n=150)
 Bleeding 6 (4.0)
  Mild 5 (3.3)
  Moderate 1 (0.7)
  Severe 0 (0.0)
 Local infectionb 1 (0.7)
 Structural 0 (0.0)
 Other (incomplete incision)c 3 (2.0)
Parentala Satisfaction at 6 weeks
 Completely or highly satisfied with procedure (n=137) 125 (91.2)
 Would recommend highly or completely EIMC (n=133) 127 (95.5)
 Would circumcise another son in the future (Y/N) (n=137) 132 (96.4)
a
Only mothers (no fathers) responding
b
Not confirmed by study team; treated with oral antibiotics
c
Device made only a partial incision requiring manual completion by the provider.
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